Swayze Eric 4

What Happened

• Eric Swayze, Executive Vice President, Research at Ionis Pharmaceuticals (IONS), acquired 256 shares on February 27, 2026. The shares were purchased at $48.87 each for a total reported cost of $12,510 (transaction coded as "J" — other acquisition/disposition). This was a purchase under the company’s Employee Stock Purchase Plan (ESPP).

Key Details

• Transaction date and price: Feb 27, 2026 — 256 shares at $48.87 per share (total reported $12,510).
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Footnote: Shares were purchased under the Ionis Amended and Restated 2000 Employee Stock Purchase Plan and may not be sold until August 27, 2026.
• Filing timeliness: Form 4 was filed March 3, 2026; this is within the SEC’s two-business-day reporting window and is therefore timely.

Context

• This was an ESPP purchase (a routine employee benefit plan), not an option exercise or an open-market sale. ESPP shares are often subject to holding restrictions and vesting/plan rules (here, a hold until Aug 27, 2026). Purchases by insiders can be of interest to investors but do not by themselves indicate future company performance.